Sponsored by:
CHOSOURCE™ CHO-K1 ADCC+ cell line
Increased therapeutic efficacy of antibodies
Horizon’s CHOSOURCE™ expression platform is used globally for development of biological therapies. Until now the platform has consisted of the CHO-K1 suspension adapted cell line with the Glutamine Synthetase gene (GS) knocked out (KO), for the purpose of providing a robust industry standard selection system, and a dual promoter expression vector for expression of functional antibodies.
This CHOSOURCE CHO-K1 GS KO cell line is currently used worldwide by over 100 pharma, biotech and Contract Manufacturing Organisations (CMO’s) for the discovery, development and manufacture of human and animal biotherapeutics as well as diagnostics and vaccines. To continue to build on the capabilities of this CHOSOURCE expression platform, we have developed an additional CHO-K1 cell line; CHOSOURCE CHO-K1 ADCC+ cell line.
CHOSOURCE CHO-K1 ADCC+ cell line has been built on our existing CHOK1 GS-KO background by eliminating the cell’s natural fucosylation activity and therefore is able to express antibodies and other fusion proteins with glycoforms completely lacking fucose. The absence of fucose has been shown to increase the Antibody Dependent Cellular Cytotoxicity (ADCC) activity.
The use of ADCC-enhanced therapeutics can result in increased potency, and by increasing its therapeutic window, may help reduce dosage requirements and therefore reduce side effects for the patients.
All benefits of which are particularly pertinent in oncology, anti-infectious and also anti-inflammatory conditions.The ultimate aim of producing such as cell line capable of producing afucosylated antibodies is to provide our new and existing customers with the tools required to develop superior therapies.
